More Than 20% of Lilly Revenue in Fourth Quarter 2007 Due to Zyprexa Sales

OPEN MINDS On-Line News In the fourth quarter that ended December 31, 2007, Eli Lilly and Company reported total sales revenue of $5.19 billion; about 20% of that amount was due to sales of Zyprexa, its schizophrenia medication, which were $1.3 billion. Zyprexa sales revenues were 10% higher than in the same quarter of 2006. United States sales of Zyprexa increased by 11%, to $608.6 million, due to higher prices and increased volume caused by variations in wholesaler buying patterns; however, unit demand in the United States was generally flat.   International sales of Zyprexa sales increased . . .